187 related articles for article (PubMed ID: 15138642)
1. [Clinical research with pharmaceutical agents in Germany: effects of the 12th amendment to the German Drug Law].
Götte D; Weihrauch TR
Internist (Berl); 2004 Jun; 45 Suppl 1():S48-54. PubMed ID: 15138642
[TBL] [Abstract][Full Text] [Related]
2. [The 12th German Drug Law (AMG) amendment: an obstruction for non-commercial clinical trials?].
Schwarz S; Frölich L; Striebel JP; Hennerici MG
Dtsch Med Wochenschr; 2007 Jan; 132(3):108-12. PubMed ID: 17219346
[No Abstract] [Full Text] [Related]
3. [Reorganization of the procedures and the tasks of the responsible ethics committees after the 12th AMG amendment. Concepts of the permanent working group of the medical ethics committees in Germany].
Wessler I; Burger R; Doppelfeld E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):155-67. PubMed ID: 15726456
[TBL] [Abstract][Full Text] [Related]
4. [Consequences of the 12th AMG amendment on the conduct of non-commercial clinical trials].
Rossion I
Urologe A; 2005 Dec; 44(12):1444-8. PubMed ID: 16283155
[TBL] [Abstract][Full Text] [Related]
5. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
[TBL] [Abstract][Full Text] [Related]
6. [Changes in the German Medicinal Product Act imposed by the EU regulation on clinical trials].
Nickel L; Seibel Y; Frech M; Sudhop T
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):804-811. PubMed ID: 28664271
[TBL] [Abstract][Full Text] [Related]
7. [The 12th amendment to the German Drug Law. Chances and obstacles for investigator-initiated clinical trials].
Dreier G; Marx C; Schmoor C; Maier-Lenz H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):445-52. PubMed ID: 15830256
[TBL] [Abstract][Full Text] [Related]
8. [Joint pilot project of the German higher federal authorities and ethics committees on implementing the EU Regulation on clinical trials].
Sudhop T; Grass G; Wessler I
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):817-825. PubMed ID: 28664274
[TBL] [Abstract][Full Text] [Related]
9. [Clinical trials with minors in Germany--effects of the 12th amendment to the German Drug Code on the numbers of applications to Institutional Review Boards (IRB)].
Kölch M; Märsch C; Fegert JM; Lippert HD
Gesundheitswesen; 2009 Mar; 71(3):127-33. PubMed ID: 19221985
[TBL] [Abstract][Full Text] [Related]
10. [The effects of the 12th and 14th amendments to the AMG (Medical Preparations Act) on paediatric pharmaceutical research--a survey of the new regulations].
Kölch M; Lippert HD; Fegert JM
Z Kinder Jugendpsychiatr Psychother; 2006 Mar; 34(2):117-26. PubMed ID: 16610597
[TBL] [Abstract][Full Text] [Related]
11. [The impact of the EU Regulation 536/2014 on the tasks and functioning of ethics committees in Germany].
Hasford J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):830-835. PubMed ID: 28638934
[TBL] [Abstract][Full Text] [Related]
12. [The off-label-prescription of TNF-alpha blocking agents for spondyloarthropathies in the context of recent statement by a German federal court].
Sieper J
Z Rheumatol; 2002 Dec; 61(6):688-93. PubMed ID: 12491132
[TBL] [Abstract][Full Text] [Related]
13. [Responsibilities of ethics committees].
von Bergmann K
Med Klin (Munich); 2000 May; 95(1 Spec No):15-7. PubMed ID: 10851843
[TBL] [Abstract][Full Text] [Related]
14. [Consequences of the German AMNOG for the identification of study objectives to demonstrate clinical efficacy and cost effectiveness of innovative drugs].
Götte D
Dtsch Med Wochenschr; 2012 Feb; 137(6):274-80. PubMed ID: 22270904
[TBL] [Abstract][Full Text] [Related]
15. Germany opposes EU plans for regulating clinical trials owing to lack of ethical standards.
Tuffs A
BMJ; 2012 Oct; 345():e6640. PubMed ID: 23033377
[No Abstract] [Full Text] [Related]
16. [The financing and price regulation of drugs in the Spanish National Health System: changes and continuity].
Puig-Junoy J
Gac Sanit; 2007; 21(1):1-4. PubMed ID: 17306178
[No Abstract] [Full Text] [Related]
17. [Off-label use in dermatological practice. The conflict between professional duty and legal requirements].
Brunne V; Mertins G; Reimann G; Brockmeyer NH
Hautarzt; 2004 Aug; 55(8):727-34. PubMed ID: 15241515
[TBL] [Abstract][Full Text] [Related]
18. [The costs of new drugs compared to current standard treatment].
Ujeyl M; Schlegel C; Gundert-Remy U
Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):461-7. PubMed ID: 24238023
[TBL] [Abstract][Full Text] [Related]
19. [Effects of the 12th amendment to the German drug code on investigator-initiated clinical trials].
Kehrel U
Gesundheitswesen; 2011 Oct; 73(10):696-701. PubMed ID: 20859850
[TBL] [Abstract][Full Text] [Related]
20. [Compassionate use of non-approved medicinal products. Legal basis and guidelines].
Sudhop T
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):439-43. PubMed ID: 19343282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
